 Antineoplastic Agents
"Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
| Descriptor ID |
D000970
|
| MeSH Number(s) |
D27.505.954.248
|
| Concept/Terms |
Antineoplastic Agents- Antineoplastic Agents
- Agents, Antineoplastic
- Antineoplastic Drugs
- Drugs, Antineoplastic
- Antineoplastics
- Chemotherapeutic Anticancer Drug
- Drug, Chemotherapeutic Anticancer
- Antitumor Drugs
- Drugs, Antitumor
- Cancer Chemotherapy Agents
- Agents, Cancer Chemotherapy
- Chemotherapy Agents, Cancer
- Cancer Chemotherapy Drugs
- Chemotherapy Drugs, Cancer
- Drugs, Cancer Chemotherapy
- Chemotherapeutic Anticancer Agents
- Agents, Chemotherapeutic Anticancer
- Anticancer Agents
- Agents, Anticancer
- Antitumor Agents
- Agents, Antitumor
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents".
This graph shows the total number of publications written about "Antineoplastic Agents" by people in this website by year, and whether "Antineoplastic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 5 | 1 | 6 | | 1997 | 4 | 4 | 8 | | 1998 | 9 | 4 | 13 | | 1999 | 11 | 5 | 16 | | 2000 | 8 | 5 | 13 | | 2001 | 5 | 7 | 12 | | 2002 | 19 | 7 | 26 | | 2003 | 16 | 9 | 25 | | 2004 | 19 | 9 | 28 | | 2005 | 22 | 10 | 32 | | 2006 | 30 | 8 | 38 | | 2007 | 47 | 14 | 61 | | 2008 | 39 | 17 | 56 | | 2009 | 39 | 23 | 62 | | 2010 | 39 | 17 | 56 | | 2011 | 49 | 17 | 66 | | 2012 | 45 | 27 | 72 | | 2013 | 54 | 28 | 82 | | 2014 | 55 | 23 | 78 | | 2015 | 60 | 27 | 87 | | 2016 | 71 | 43 | 114 | | 2017 | 60 | 29 | 89 | | 2018 | 63 | 22 | 85 | | 2019 | 46 | 19 | 65 | | 2020 | 43 | 11 | 54 | | 2021 | 37 | 3 | 40 | | 2022 | 27 | 4 | 31 | | 2023 | 31 | 1 | 32 | | 2024 | 24 | 23 | 47 | | 2025 | 39 | 7 | 46 | | 2026 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.
-
Zhang L, Iliescu C, Ferencik M, Finamore V, Beavers C, Patel AR, Ghoshhajra B, Milgrom S, Dent S, Baldassarre LA, Jaffe IZ, Lopez-Mattei J. Coronary Atherosclerosis in Patients With Cancer and Survivors: A Scientific Statement From the American Heart Association. Circulation. 2026 Mar 10; 153(10):e916-e933.
-
Dimopoulos MA, Lonial S, Chng WJ, Iida S, Mateos MV, Morgan GJ, Li C, Byrne C, Suryanarayan K, Labotka R, Rajkumar SV. Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myeloma. Blood Cancer J. 2025 Dec 04; 16(1):15.
-
Shulman DS, Vo KT, Balis FM, Lindsay H, Bagatell R, Place AE, Chi SN, Shusterman S, Ezrre S, Czaplinski J, Bhushan K, Kao PC, London WB, DuBois SG. A Phase 1 Trial of Fimepinostat in Children and Adolescents With Relapsed and Refractory Solid and CNS Tumors. Cancer Med. 2025 Dec; 14(23):e71417.
-
DuBois SG, Moreno L, Bagatell R, Cheung NK, Gray JC, Locatelli F, Reynolds CP, Rossig C, Sondel PM, Drezner N, Kholmanshikh O, Bird N, Day L, Ludwinski D, Scobie N, Pons Sanz V, Ball S, Hammer B, Alvarez Rojo I, Meager D, Sveistrup J, Berlanga P, Casanova M, Glade-Bender J, Macy M, Morgenstern DA, Owens C, Weigel BJ, Pappo A, Nysom K, Anderson J, Ligas F, Lesa G, Donoghue M, Karres D, Vassal G. Paediatric Strategy Forum for medicinal product development of agents targeting GD2 ganglioside in children and adolescents with cancer. Eur J Cancer. 2025 Dec 09; 231:116093.
-
Major A, Paje DG, Taxbro K, McQuilten Z, Kin AD, Alexandrou E, Hsaiky L, Hill J, Moss JG, Kamboj M, White SB, Horowitz JK, McLaughlin E, Flanders SA, Bernstein SJ, Chopra V. The Michigan Appropriateness Guide for Intravenous Catheters in Adult Patients With Cancer (MAGIC-ONC): Results From a Multispecialty Panel Using the RAND/UCLA Appropriateness Method. Ann Intern Med. 2025 Dec; 178(12_Supplement):S143-S177.
-
Schreiber AR, Verduzco-Aguirre HC, Giangiuli S, Aranda-Gutierrez A, Roy S, Soto-Perez-de-Celis E. A review of current and emerging therapies in breast cancer: implications for older adults. Expert Rev Clin Pharmacol. 2025 Oct; 18(10):1-16.
-
Strong Caldwell A, Milner DC, Mehta NB, Marin AI, Gill ZS, Manoharan N. MERTK INHIBITOR-ASSOCIATED RETINAL TOXICITY IN A HUMAN. Retin Cases Brief Rep. 2025 Nov 01; 19(6):807-810.
-
Liu T, Zhou JH, Gong Y, Zhang Y, Ma Y, Zhang X, Minhajuddin M, Song W, Zhuang Z, Vujovic A, Lu Y, Jia A, Guo R, Ren R, Zhou L, Xiong Y, Huang L, Du X, Zhao TJ, Li P, Jordan CT, Ye H. A generalized strategy to kill leukemic cells by targeting the regulatory systems governing mitochondrial membrane potential. Cell Rep. 2025 Nov 25; 44(11):116496.
-
Mukherjee N, Sheetz J, Shellman YG. Targeting the BCL2 Family: Advances and Challenges in BH3 Mimetic-Based Therapies. Int J Mol Sci. 2025 Oct 10; 26(20).
-
Graham-Gurysh EG, Woodring RN, Simpson SR, Mendell SE, Lukesh NR, Pena ES, Moore KM, Ontiveros-Padilla LA, Hendricksen AT, Lopez AM, Williamson GL, Murphy CT, Genito CJ, Hipp KA, Singh G, Zamboni WC, Hingtgen SD, Fecci PE, Bachelder EM, Ainslie KM. Post-resection delivery of a TLR7/8 agonist from a biodegradable scaffold achieves immune-mediated glioblastoma clearance and protection against tumor challenge in mice. Nat Commun. 2025 Sep 29; 16(1):8603.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|